OncoMatch/Clinical Trials/NCT05633667
Study of Novel Treatment Combinations in Patients With Lung Cancer
Is NCT05633667 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments for lung cancer.
Treatment: Zimberelimab (ZIM) · Domvanalimab (DOM) · Sacituzumab govitecan-hziy (SG) · Etrumadenant (ETRUMA) · Carboplatin · Cisplatin · Pemetrexed · Paclitaxel · Nab-paclitaxel · Docetaxel · Nivolumab — The goal of this platform clinical trial is to test how well novel treatment combinations work in participants with lung cancer. Substudy-01 will compare the different novel combinations versus standard of care in participants with metastatic (cancer that has spread) non-small-cell lung cancer (NSCLC) who have not been treated before. Substudy-02 will compare the different novel combination versus standard of care in participants with cancer that has progressed after receiving previous treatment for metastatic NSCLC. Substudy-03 will compare the different novel combinations versus standard of care in participants with resectable stage II-III NSCLC. The primary objectives of this study are: Substudy-01 and Substudy-02: To evaluate the objective response rate (ORR) assessed per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1). Substudy-03: To evaluate the efficacy of treatment combinations based on complete pathological response (pCR) rate.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Disease stage
Required: Stage IV, II, IIIA, IIIB (T[3-4]N2) (AJCC Edition 8)
Stage IV NSCLC. Previously untreated individuals with resectable (Stage II, IIIA, IIIB (T[3-4]N2)) NSCLC (per American Joint Committee on Cancer (AJCC) Edition 8).
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: targeted therapy — for actionable EGFR, ALK, or other known genomic alterations
In individuals with nonsquamous histology and actionable EGFR, ALK, or other known genomic alterations must have received treatment with at least 1 targeted therapy to the appropriate genomic alteration.
Cannot have received: systemic therapy
No prior systemic treatment for metastatic NSCLC.
Cannot have received: anticancer therapy
Received previous anticancer therapy within 4 weeks prior to enrollment.
Cannot have received: systemic therapy
NSCLC previously treated with systemic therapy or radiotherapy.
Cannot have received: radiotherapy
NSCLC previously treated with systemic therapy or radiotherapy.
Cannot have received: anti-PD-(L)-1 therapy
Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).
Cannot have received: immune checkpoint inhibitor
Received prior treatment with any anti-PD-(L)-1 or other immune checkpoint inhibitors (CPIs).
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate end-organ function
Liver function
adequate end-organ function
Adequate hematologic and end-organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- US Oncology Investigational Products Center (IPC),Substudy-01 · Fairfax, Virginia
- US Oncology Investigational Products Center (IPC),Substudy-02 · Fairfax, Virginia
- Fred Hutchinson Cancer Center,Substudy-01 · Seattle, Washington
- Fred Hutchinson Cancer Center,Substudy-02 · Seattle, Washington
- Arizona Oncology Associates,Substudy-01 · Tucson, Arizona
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify